Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 17/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18748574 | 0.78 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL1387331 | 0.78 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL22544383 | 0.75 | SLC10A2 (0.50) | SLC10A2 | |
| SCHEMBL17528459 | 0.74 | SLC10A2 (0.53) | SLC10A2 | |
| SCHEMBL16067963 | 0.71 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL20169922 | 0.70 | SLC10A2 (0.49) | SLC10A2 | |
| SCHEMBL13334805 | 0.69 | TRPM5 (0.38) | SLC10A2 | |
| SCHEMBL12070257 | 0.69 | TRPM5 (0.38) | SLC10A2 | |
| SCHEMBL12070260 | 0.69 | SLC10A2 (0.51) | SLC10A2KMT2A | |
| SCHEMBL8378689 | 0.68 | SLC10A2 (0.73) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169217-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | LUMENA PHARMACEUTICALS LLC (US) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169217-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885MEN1 3173/4885ALDH1A1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.